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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
RTS,S/AS01 Malaria Vaccine in African Children
To the Editor: In the article by the RTS,S Clini-
cal Trials Partnership (Nov. 17 issue)1 on the 
phase 3 trial of RTS,S (ClinicalTrials.gov num-
ber, NCT00866619), an analysis of the efficacy of 
RTS,S/AS01 against severe malaria was not re-
ported for the vaccine’s target age group of in-
fants who were 6 to 12 weeks of age and who 
received RTS,S with routine childhood vaccines. 
However, this efficacy can be calculated as 17% 
(P = 0.23) (see Table 1 in the Supplementary Ap-
pendix, available with the full text of this letter at 
NEJM.org). Therefore, in the age group for whom 
RTS,S is intended, the efficacy against severe 
malaria was minimal. This finding was unex-
pected,2 and the goal of 50% efficacy against se-
vere malaria of the Malaria Vaccine Technology 
Roadmap (www.malariavaccine.org/files/Malaria_ 
Vaccine_TRM_Final.pdf) was not met.
Moreover, in the reported 12-month data, 
there was already significant waning of vaccine 
efficacy against clinical malaria, and the 17% 
efficacy against severe malaria in young infants 
was measured over an average of 7 months. 
Thus, over longer periods, there will probably be 
less efficacy. Lower vaccine immunogenicity3,4 
and the rapid waning of induced antibodies and 
vaccine efficacy5 shown in phase 2a and field 
trials1,4,5 probably contribute to the lower efficacy 
of RTS,S in young infants. By the time severe 
malaria develops in infants vaccinated at 2 to 
4 months of age (for instance, 7 months after 
vaccination), vaccine efficacy may be minimal.
Adrian V.S. Hill, D.M., D.Phil.
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To the Editor: In the fight against malaria, 
people must be careful not to overestimate the 
impact of any single new intervention. I have 
concerns that the vaccine’s researchers “did not 
observe a reduction in the rate of death from ma-
laria or from any cause” in the vaccine group. I 
also am concerned that the article may be mis-
leading when the authors state that the “vaccine 
reduced malaria by half.” As a Peace Corps volun-
teer in Senegal, I saw how news could be mis-
interpreted in rural villages. In my current pro-
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grams for malaria prevention, I have also seen 
the positive impact of our work. The hope sur-
rounding this vaccine may tempt populations in 
malaria-endemic countries to abandon proven 
methods such as insecticide-treated bed nets. 
This would be a tragedy, because such public 
health interventions are working and have been 
associated with a 20% decrease in deaths from 
malaria over the past 10 years and with complete 
eradication of the disease in several countries.1
Andrew C.L. Sherman, M.D.
University of Rochester 
Rochester, NY 
andrew_sherman@urmc.rochester.edu
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To the Editor: The RTS,S Clinical Trials Part-
nership describes the favorable interim results of 
the first large-scale vaccine field trial ever con-
ducted for a human parasitic disease, in this case 
Plasmodium falciparum malaria, which is  respon-
sible for most of approximately 655,000 yearly 
deaths from malaria.1 We believe that the release 
of these initial 14-month data showing an approx-
imate 56% reduction in the incidence of first 
clinical malaria episodes in the older cohort of 
children (5 to 17 months of age) will enable early 
consideration of the potential impact of the vac-
cine in sub-Saharan Africa by public health plan-
ners. This consideration will facilitate efficient 
review by the European Medicines Agency once 
the trial is complete, accelerating licensure. Should 
the final results of the study, expected in late 
2014,2  confirm the net benefits seen in this in-
terim analysis, every day saved on the pathway to 
implementing the RTS,S immunization program 
will reduce suffering and potentially save lives.
Thomas L. Richie, M.D., Ph.D.
U.S. Military Malaria Vaccine Program 
Silver Spring, MD 
thomas.richie@med.navy.mil
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The Authors Reply: Hill’s reanalysis of our data 
is flawed, and the calculated estimate of vaccine 
efficacy in the younger age category is incorrect. 
Hill erroneously assumed that all cases of severe 
malaria that did not occur during the 12-month 
postvaccination period in the first 6000 children 
enrolled in the older age category occurred in the 
younger age category. He overlooked the fact that 
an additional 2923 children were enrolled in the 
older age category and that follow-up extended up 
to 22 months after vaccination, providing more 
participants and a longer follow-up period dur-
ing which cases of severe malaria in these older 
children contributed to the pooled analysis (see 
Table 7 in the Supplementary Appendix of our ar-
ticle, available at NEJM.org). Hill incorrectly as-
signed 187 cases of severe malaria to the younger 
age category, whereas there were only 66 cases 
(Table 10a in the Supplementary Appendix).
The lower estimate of vaccine efficacy against 
severe malaria in the pooled age categories as 
compared with the first 6000 children in the 
older age category who were followed for 12 
months might be explained by lower vaccine ef-
ficacy against severe malaria in the younger age 
category. A second explanation could be waning 
protection. Vaccine efficacy in the younger age 
category will be analyzed later this year, after 
participants in the younger age category have 
completed 12 months of follow-up in accordance 
with our predefined analysis plan. Data on the 
duration of protection will be available in 2014. 
The analysis plan was designed to allow dissemi-
nation of key findings as soon as they become 
available, even though this results in our sharing 
data without being able to fully explain all find-
ings. We think that this approach is worthwhile, 
since the information we have shared has been 
useful in stimulating debate in the scientific com-
munity and among health authorities on the po-
tential role of this vaccine and in refining fore-
casts to ensure manufacturing capacity for timely 
availability of vaccine.
Sherman recognizes the need for continued 
support for proven methods for malaria preven-
tion, including insecticide-treated bed nets. As 
emphasized in our article, the RTS,S/AS01 ma-
laria vaccine is not intended as an alternative to 
established malaria-control measures but rather 
as an additional tool for integrated control. Dur-
ing the phase 3 RTS,S/AS01 trial, every effort has 
been made to ensure that all enrolled children 
sleep under an insecticide-treated bed net. Our 
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findings thus far show that in a population in 
which approximately 75% of the children were 
using insecticide-treated bed nets, cases of clin-
ical malaria were reduced by 55% in the children 
who received the RTS,S/AS01 vaccine, indicating 
that the RTS,S/AS01 malaria vaccine could be an 
important addition to established malaria-con-
trol tools.
Mary J. Hamel, M.D.
Centers for Disease Control and Prevention 
Atlanta, GA
Salim Abdulla, M.D., Ph.D.
Ifakara Health Institute 
Dar es Salaam, Tanzania
Brian Greenwood, M.D.
London School of Hygiene and Tropical Medicine 
London, United Kingdom
for the RTS,S Synthesis and Writing Committee
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determination or policy.
Since publication of their article, the authors report no fur-
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Escherichia coli O104:H4 Outbreak in Germany
To the Editor: In their article on last year’s out-
break of Escherichia coli O104:H4 in Germany, 
Frank et al. (Nov. 10 issue)1 report some striking 
features. Nearly 90% of patients were adults (me-
dian age, 42 years), with an overrepresentation of 
women (68%). In pediatric series, girls also pre-
dominate over boys but not to such a marked 
degree.2 Moreover, the attack rate of the hemo-
lytic–uremic syndrome associated with diarrhea 
(845 of 3816 cases, or 22%) in Germany exceeded 
the rate of 5 to 15% in most previous reports of 
outbreaks. In children, the administration of an-
tibiotics to empirically treat the prodromal en-
teritis has been associated with a significantly 
increased risk of progression to the hemolytic–
uremic syndrome.3,4 This finding is supported by 
preclinical data in the infection model in the 
gnotobiotic piglet.5 The pattern of antibiotic use 
to treat bloody diarrhea may differ between chil-
dren and adults. This may explain the high pro-
portion of patients with the hemolytic–uremic 
syndrome in the German outbreak, independent 
of the pathogenicity of the unusual bacterial 
strain. Clarification of antibiotic use to treat the 
antecedent enteritis may shed light on this par-
ticular outbreak and help guide the prescription 
of antibiotics in patients with gastroenteritis and 
bloody diarrhea.
Howard Trachtman, M.D.
NYU Langone Medical Center 
New York, NY 
howard.trachtman@nyumc.org
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The Authors and a Colleague Reply: Tracht-
man hypothesizes that the frequent use of anti-
microbial drugs in adults may explain the un-
usually high proportion of patients with the 
hemolytic–uremic syndrome in the German out-
break of Shiga-toxin–producing E. coli O104:H4 
infection. The outpatient use of antimicrobial 
drugs in Germany is low as compared with inter-
national standards,1 and the administration of 
such drugs is generally not recommended for the 
empirical treatment of acute (bloody) diarrhea. 
In the case of Shiga-toxin–producing  E. coli in-
fection, it is recommended that practitioners re-
frain from administering antimicrobials.2,3 In 
hypothesis-generating interviews that we con-
ducted early in the outbreak investigation, only 
6 of 36 adult patients with the hemolytic–uremic 
syndrome (17%) for whom data were available 
reported having taken antimicrobials in the course 
of their illness or having received a correspond-
ing prescription. This finding is consistent with 
treatment regimens reported to us by many hos-
pitals and specific recommendations issued dur-
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